OTCMKTS:HBPCF Helix Biopharma (HBPCF) Stock Price, News & Analysis $0.77 0.00 (0.00%) As of 10/23/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartEarnings About Helix Biopharma Stock (OTCMKTS:HBPCF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Helix Biopharma alerts:Sign Up Key Stats Today's Range$0.77▼$0.7750-Day Range$0.77▼$1.7152-Week Range$0.77▼$1.73VolumeN/AAverage Volume10 shsMarket Capitalization$58.81 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Helix BioPharma Corp. is a Canadian clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer. The company’s research is centered on treatments designed to act within the tumor microenvironment, with the goal of improving the effectiveness of oncology medicines. Its lead product candidate is L-DOS47, an antibody-enzyme conjugate designed to target CEACAM6, a protein expressed on the surface of certain cancer cells. L-DOS47 combines a targeting antibody fragment with urease, an enzyme intended to generate ammonia in the tumor environment and potentially disrupt conditions that support tumor growth. The candidate has been evaluated in clinical development for cancers including pancreatic adenocarcinoma and non-small cell lung cancer. Helix BioPharma is based in Canada and has historically focused its development activities on oncology programs intended for international clinical and commercial markets. As a development-stage biotechnology company, its operations and future prospects depend on the progress of its drug candidates through clinical testing, regulatory review and potential commercialization.AI Generated. May Contain Errors. Read More Receive HBPCF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Helix Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HBPCF Stock News HeadlinesHelix BioPharma Files Interim Financial Statements for April 2025June 16, 2025 | tipranks.comHelix BioPharma Appoints New CFO to Drive Strategic GrowthJune 2, 2025 | tipranks.comFDA clears next-gen therapy with 10 to 40 times greater potencyTime-lapse footage from a recent clinical study shows Natural Killer cells attacking and eliminating cancer cells - and early human data revealed up to a 63.7 percent reduction in cancer burden. One NASDAQ-listed biotech's TriKE platform is designed to keep these immune cells locked onto tumors longer. Its next-generation version, showing potential for 10 to 40 times greater potency, has just cleared an important FDA milestone.October 26 at 1:00 AM | Market Tactic (Ad)Helix BioPharma Secures $13 Million Financing to Advance Cancer TherapiesMay 14, 2025 | tipranks.comHelix BioPharma Appoints New CEO to Propel Clinical AdvancementsApril 10, 2025 | tipranks.comHelix BioPharma Engages ITG for Market-Making ServicesApril 3, 2025 | tipranks.comHelix BioPharma Corp. Announces Key Decisions from Annual MeetingMarch 26, 2025 | tipranks.comHelix BioPharma Releases Interim Financial Statements for January 2025March 18, 2025 | tipranks.comSee More Headlines HBPCF Stock Analysis - Frequently Asked Questions How have HBPCF shares performed this year? Helix Biopharma's stock was trading at $1.7338 at the start of the year. Since then, HBPCF shares have decreased by 55.6% and is now trading at $0.77. How were Helix Biopharma's earnings last quarter? Helix Biopharma Corp. (OTCMKTS:HBPCF) announced its quarterly earnings results on Friday, June, 12th. The company reported ($0.01) earnings per share for the quarter, beating analysts' consensus estimates of ($0.08) by $0.07. How do I buy shares of Helix Biopharma? Shares of HBPCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings6/12/2026Today10/26/2026Next Earnings (Estimated)10/29/2026Fiscal Year End7/31/2027Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:HBPCF CIKN/A Webwww.helixbiopharma.com Phone905-841-2300Fax905-841-2244Employees7Year Founded1995Profitability EPS (Trailing Twelve Months)($0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$3.73 million Net MarginsN/A Pretax MarginN/A Return on Equity-21.61% Return on Assets-17.14% Debt Debt-to-Equity RatioN/A Current Ratio0.45 Quick Ratio0.45 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.15 per share Price / Book5.13Miscellaneous Outstanding Shares76,380,000Free Float70,573,000Market Cap$58.81 million OptionableNot Optionable Beta0.11 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (OTCMKTS:HBPCF) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersNNVC Is Heating Up as Its Antiviral Pipeline Advances!NanoViricides (NYSE American: NNVC) is advancing NV-387, a broad-spectrum antiviral candidate, into Phase II t...Equiscreen | Sponsored80 Days Until America's Rare Earth Supply Chain ShiftChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | SponsoredWhy tech stocks are deadAI skeptics see dot-com era warning signs, and they have a point. But the real opportunity may not be in the b...Porter & Company | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredFDA clears next-gen therapy with 10 to 40 times greater potencyTime-lapse footage from a recent clinical study shows Natural Killer cells attacking and eliminating cancer ce...Market Tactic | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Helix Biopharma Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Helix Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
